Kent, UK. - When Pfizer checked out of their bespoke research and development site in Sandwich, Kent, in the far south east of the United Kingdom, there was a degree of uncertainty and cynicism on how the site would move forward and jobs be re-created in the region.
Much to the credit of the team at Discovery Park and the local authorities in Kent along with investment promotion agency, Locate in Kent, the 1.5million square foot is going through a significant renaissance and is now home to a diverse range of British and global businesses creating a legacy of their own.
The Park can now rightly boast that it is one of Europe’s leading science and technology parks with world class facilities that now host a cluster of businesses from the life science, pharmaceutical, biotechnology, science and technology sectors.
Management at Discovery Park have the stated aim to attract independent parties (such as innovative start-ups, SMEs, as well as research and knowledge dissemination organisations and not-for-profit organisations) who work together to stimulate innovative activity through promotion, sharing of facilities and exchange of knowledge and expertise and by contributing effectively to knowledge transfer, networking, information dissemination and collaboration among the undertakings and other organisations in the cluster.
The Park covers 220 acres.Spaces range from specialist laboratories and commercial office space through to practical warehousing and manufacturing facilities and bespoke accommodation is available.
Discovery Park has become a real success story for Kent. To find out more go to www.discovery-park.co.uk/ .
Discovery Park resident, Levicept Ltd closes £10 Million financing round
A tenant at Discovery Park, in Sandwich, Kent has announced that it has closed £10 million Series A financing with Advent Life Sciences, Gilde Healthcare and Index Ventures. In addition, Levicept was awarded a £2.4 million grant from the Biocatalyst Fund of the UK’s innovation agency, Innovate UK, in April 2014.
The company, Levicept Ltd, was founded in 2012 by Simon Westbrook, a former Pfizer scientist, and is a biopharmaceutical company focused on the development of LEVI-04, a p75 neurotrophin receptor fusion protein (p75NTR-Fc) for chronic pain indications.
Proceeds from the financing will be used to advance the proprietary neurotrophin-modulating fusion protein from preclinical research to a proof-of-concept first-in-human study in osteoarthritis patients.
“The ongoing support from our existing investor and new involvement from investors with deep experience in the life sciences is testament to the exciting preclinical data already obtained with p75NTR-Fc,” said Simon Westbrook, Chief Executive Officer of Levicept,
“LEVI-04 has shown the potential to provide a truly differentiated treatment for patients with osteoarthritis in a clinically precedented pathway”.
Raj Parekh (Advent Life Sciences) and Arthur Franken (Gilde Healthcare Partners) will be joining David Grainger (Index Ventures), Kevin Johnson (Executive Chairman Levicept) and Simon Westbrook (CEO Levicept) to form the new board of Levicept Ltd.